Clinical trial • Phase I • Oncology
LY4170156 for Ovarian cancer | Endometrial cancer | Cervical cancer | Non-small cell lung cancer | Triple-negative breast cancer | Pancreatic cancer | Colorectal cancer
Phase I trial of LY4170156 for Ovarian cancer | Endometrial cancer | Cervical cancer | Non-small cell lung cancer | Triple-negative breast cancer | Pancre…
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Ovarian cancer | Endometrial cancer | Cervical cancer | Non-small cell lung cancer | Triple-negative breast cancer | Pancreatic cancer | Colorectal cancer
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 22-04-2024
- First CTIS Authorization Date
- 09-08-2024
Trial design
Phase I trial across 8 sites in France, Italy, Spain.
- Target Sample Size
- 316
Eligibility
Recruits 316 Vulnerable population selected: true; no further details on consent or assent handling are provided in the available documents..
- Vulnerable Population
- Vulnerable population selected: true; no further details on consent or assent handling are provided in the available documents.
Recruitment
- Planned Sample Size
- 316
- Recruitment Window Months
- 37
- Consent Approach
- Vulnerable population selected; the informed consent and assent process (who provides consent, age-specific documents, languages) is not specified in the available CTIS data.
Geography
- Total Number Of Sites
- 8
- Total Number Of Participants
- 223
France
- Earliest CTIS Part Ii Submission Date
- 01-08-2024
- Latest Decision Or Authorization Date
- 20-03-2026
- Processing Time Days
- 596
- Number Of Sites
- 3
- Number Of Participants
- 96
Sites
- Site Name
- Institut De Cancerologie De L Ouest
- Department Name
- Medical Oncology
- Contact Person Name
- Mario Campone
- Contact Person Email
- mario.campone@ico.unicancer.fr
- Site Name
- Centre Leon Berard
- Department Name
- Medical Oncology
- Contact Person Name
- Isabelle Ray-Coquard
- Contact Person Email
- isabelle.ray-coquard@lyon.unicancer.fr
- Site Name
- Institut Universitaire Du Cancer Toulouse-Oncopole
- Department Name
- Medical Oncology
- Contact Person Name
- Carlos Gomez-Roca
- Contact Person Email
- gomez-roca.carlos@iuct-oncopole.fr
Italy
- Earliest CTIS Part Ii Submission Date
- 19-07-2024
- Latest Decision Or Authorization Date
- 18-03-2026
- Processing Time Days
- 576
- Number Of Sites
- 2
- Number Of Participants
- 35
Sites
- Site Name
- Humanitas Mirasole S.p.A.
- Department Name
- Gynecologic Oncology Unit
- Contact Person Name
- Domenica Lorusso
- Contact Person Email
- domenica.lorusso@sanpiox.humanitas.it
- Site Name
- Istituto Europeo Di Oncologia S.r.l.
- Department Name
- Divisione di Sviluppo di Nuovi Farmaci per Terapie Innovative
- Contact Person Name
- Giuseppe Curigliano
- Contact Person Email
- Giuseppe.curigliano@ieo.it
Spain
- Earliest CTIS Part Ii Submission Date
- 10-07-2024
- Latest Decision Or Authorization Date
- 13-02-2026
- Processing Time Days
- 552
- Number Of Sites
- 3
- Number Of Participants
- 92
Sites
- Site Name
- Hospital Clinico Universitario De Valencia
- Department Name
- Medical Oncology
- Contact Person Name
- Jose Alejandro Perez Fidalgo
- Contact Person Email
- japfidalgo@msn.com
- Site Name
- Hospital Universitario 12 De Octubre
- Department Name
- Medical Oncology
- Contact Person Name
- Ainhoa Madariaga Urrutia
- Contact Person Email
- Ainhoa.madariaga@salud.madrid.org
- Site Name
- Hospital Universitari Vall D Hebron
- Department Name
- Medical Oncology
- Contact Person Name
- Roberta Mazzeo
- Contact Person Email
- robertamazzeo@vhio.net
Sponsor
Primary sponsor
- Full Name
- Eli Lilly & Co.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- LY4170156
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)